KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial.

Ayal A Aizer, Kee-Young Shin, Paul J Catalano, Ivy Ricca, Marciana Johnson, Grant Benham, Kristin Roper, Beverly Spicer, Eileen Mann, Jennifer Nosker, Michael W Parsons, Mallika L Mendu, Jaroslaw Hepel, Fallon Chipidza, Monica Krishnan, Diana D Shi, Nayan Lamba, Itai Pashtan, Luke Peng, Brian Alexander, Paul D Brown, Patrick Y Wen, Daphne A Haas-Kogan, Rifaquat Rahman, Shyam Tanguturi

JAMA 335(13) 1127-1136

PMID41712219
PMCIDPMC12921566
DOI10.1001/jama.2026.0076
发表日期2026-02-19
入排依据:The record describes a randomized Phase III trial in oncology (brain metastases) with a primary quality-of-life endpoint (patient-reported symptom severity). It does not contain a drug-containing intervention (both arms are radiation-based). It does not report a time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR data. Therefore, it does not meet the required criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

IMPORTANCE: Brain metastases are common in patients with cancer, and radiation is often used for management. Among patients with more than 4 brain metastases, the effects of stereotactic radiation targeting only individual tumors, compared with whole brain radiation with hippocampal avoidance, which radiates both tumors and normal brain, remain unknown. OBJECTIVE: To determine whether stereotactic radiation improves symptom severity and interference with daily functioning, compared with whole brain radiation with hippocampal avoidance. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, open-label, randomized clinical trial conducted at 4 United States-based centers. Eligible patients had 5 to 20 brain metastases and no prior brain-directed radiation. Enrollment occurred between April 11, 2017, and May 17, 2024 (final follow-up, March 18, 2025). INTERVENTION: Stereotactic radiation, compared with whole brain radiation with hippocampal avoidance. MAIN OUTCOMES AND MEASURES: Mean weighted patient-reported symptom severity and interference score change over 6 months postbaseline relative to baseline using the MD Anderson Symptom Inventory-Brain Tumor instrument (scale, 0-10; score change range, -10 to 10; -10 = best). A clinically meaningful Δ was defined as 0.98. RESULTS: Of 196 randomized patients (mean age, 61 years; 129 [66%] female; 176 [90%] White; median number of brain metastases, 14 [IQR, 11-18]; 49 [25%] with prior neurosurgical resection), 83 (42%) completed the 6-month assessment. For the primary outcome, between baseline and postbaseline assessments through the 6-month follow-up, stereotactic radiation changed the weighted composite MD Anderson Symptom Inventory-Brain Tumor score from 2.69 to 2.37 (mean change, -0.32) and hippocampal-avoidance whole brain radiation changed the score from 2.29 to 3.03 (mean change, 0.74) (mean difference, -1.06 [95% CI, -1.54 to -0.58]; P < .001). Related grade 3-5 adverse events occurred in 12 patients (12%) in the stereotactic radiation group and 13 patients (13%) in the hippocampal-avoidance whole brain radiation group; grade 1-3 fatigue was most frequent (27 [28%] vs 43 [44%], respectively). CONCLUSIONS AND RELEVANCE: In patients with 5 to 20 brain metastases, these findings support stereotactic radiation over hippocampal-avoidance whole brain radiation to improve symptoms and interference with daily functioning, key components of quality of life. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03075072.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。